Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Gynecologic Oncology|January 27, 2021
Optimal overall treatment time for adjuvant therapy for women with completely resected, node-positive vulvar cancerSarah Ashmore, Sarah M Crafton, Eirwen M Miller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 28, 2020
Race-driven survival differential in women diagnosed with endometrial cancers in the USAZachary D Horne, Solomiya R Teterichko, Scott M Glaser, et al.
Gynecologic Oncology|January 20, 2020
Survival disparities in vulvar cancer patients in Commission on Cancer®-accredited facilitiesNicole B Gaulin, Jamie L Lesnock, Chunqiao Tian, et al.
BMC Medical Genomics|December 1, 2020
Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroupsEirwen M Miller, Nicole E Patterson, Gregory M Gressel, et al.
Oncotarget|December 20, 2017
Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variantsEirwen M Miller, Nicole E Patterson, Jenna Marcus Zechmeister, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
Pageof 2